Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Discharge 39% Improvement Relative Risk c19hcq.org Taieb et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 926 patients in Senegal Higher discharge with HCQ (p=0.017) Taieb et al., J. Clin. Med. 2021, doi:10.3390/jcm10132954 Favors HCQ Favors control
Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020
Taieb et al., J. Clin. Med. 2021, doi:10.3390/jcm10132954
Taieb et al., Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal.., J. Clin. Med. 2021, doi:10.3390/jcm10132954
Jun 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 926 patients in Senegal, 674 treated with HCQ+AZ, showing significantly higher hospital discharge at day 15 with treatment.
risk of no hospital discharge, 38.7% lower, OR 0.61, p = 0.02, treatment 674, control 252, inverted to make OR<1 favor treatment, multivariate, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Taieb et al., 30 Jun 2021, retrospective, Senegal, peer-reviewed, 29 authors, average treatment delay 6.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal of Clinical Medicine Article Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020 Fabien Taieb 1, *, Khardiata Diallo Mbaye 2 , Billo Tall 1 , Ndèye Aïssatou Lakhe 2 , Cheikh Talla 1 , Daouda Thioub 2 , Amadou Moustapha Ndoye 1 , Daye Ka 2 , Aboubacry Gaye 1 , Viviane Marie-Pierre Cissé Diallo 2 , Ndongo Dia 1 , Pape Samba Ba 3 , Mamadou Cissé 1 , Moustapha Diop 3 , Cheikh Tidiane Diagne 1 , Louise Fortes 2,4 , Mamadou Diop 1 , Ndèye Maguette Fall 2,5 , Fatoumata Diène Sarr 1 , Margarite Diatta 1 , Mamadou Aliou Barry 1 , Aboubakar Sidikh Badiane 2,6 , Abdoulaye Seck 1 , Philippe Dubrous 1 , Ousmane Faye 1 , Inès Vigan-Womas 1 , Cheikh Loucoubar 1 , Amadou Alpha Sall 1 and Moussa Seydi 2 1   Citation: Taieb, F.; Mbaye, K.D.; Tall, 2 B.; Lakhe, N.A.; Talla, C.; Thioub, D.; Ndoye, A.M.; Ka, D.; Gaye, A.; Cissé Diallo, V.M.-P.; et al. Hydroxychloroquine and 3 Azithromycin Treatment of Hospitalized Patients Infected with 4 SARS-CoV-2 in Senegal from March 5 to October 2020. J. Clin. Med. 2021, 10, Institut Pasteur de Dakar, Dakar BP 220, Senegal; billo.tall@pasteur.sn (B.T.); ctalla@pasteur.sn (C.T.); amadoumoustapha.ndoye@pasteur.sn (A.M.N.); aboubacry.gaye@pasteur.sn (A.G.); ndongo.dia@pasteur.sn (N.D.); mamadou.cisse@pasteur.sn (M.C.); CheikhTidiane.DIAGNE@pasteur.sn (C.T.D.); mamadou.diop@pasteur.sn (M.D.); fatoumata.sarr@pasteur.sn (F.D.S.); Marguerite.diatta@pasteur.sn (M.D.); aliou.barry@pasteur.sn (M.A.B.); ablayseck@gmail.com (A.S.); Philippe.dubrous@pasteur.sn (P.D.); Ousmane.faye@pasteur.sn (O.F.); Ines.vigan-womas@pasteur.sn (I.V.-W.); cheikh.loucoubar@pasteur.sn (C.L.); Amadou.sall@pasteur.sn (A.A.S.) Service des Maladies Infectieuses et Tropicales, De Fann University Hospital Center (CNHU FANN), Dakar BP 5035, Senegal; diallokhardiata@gmail.com (K.D.M.); aissatoulakhe@gmail.com (N.A.L.); dave11690@gmail.com (D.T.); dayeka10@gmail.com (D.K.); vivich6@gmail.com (V.M.-P.C.D.); louisefortes@gmail.com (L.F.); maguifall4@gmail.com (N.M.F.); aboubakrbadiane@yahoo.fr (A.S.B.); seydim@u.washington.edu (M.S.) Hôpital Principal de Dakar, Dakar BP 220, Senegal; basambasn2000@yahoo.fr (P.S.B.); mouztaphandm@gmail.com (M.D.) Centre de Traitement des épidémies de l’Hôpital Dalal Jamm, Dakar BP 19.001, Senegal Hôpital de Diamnadio, Centre de Traitement des épidémies de l’Hôpital de Diamnadio, Bargny BP 204, Senegal Fann University Hospital, Centre de Traitement des épidémies de Touba, Touba 22300, Senegal Correspondence: fabien.taieb@pasteur.sn 2954. https://doi.org/10.3390/ 6 jcm10132954 * Academic Editors: Philippe Parola, Abstract: As of today, little data is available on COVID-19 in African countries, where the case management relied mainly on a treatment by association between hydroxychloroquine (HCQ) and azithromycin (AZM). This study aimed to understand the main clinical outcomes of COVID-19 hospitalized patients in Senegal from March to October 20202. We described the clinical characteristics of patients and analysed clinical status (alive and discharged versus hospitalized or died) at 15 days after Isolation and Treatment Centres (ITC) admission among adult patients who received HCQ plus AZM and those who did not receive this combination. A total of 926 patients were included in this analysis. Six hundred seventy-four (674) (72.8%) patients received a combination of HCQ and AZM. Results showed that the..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit